ReportGem ReportGem

U.S. COMPANY FILING

AbbVie Inc. — Form 10-Q filed 2026-08-03

Filed: 2026-08-03Company: AbbVie Inc.Ticker: ABBVExchange: NYSEForm: 10-QReport period: 2026-06-30SEC accession: 0001551152-26-000026Event: earningsMateriality: 85

Filing text preview

AbbVie's Q2 2026 net revenues rose 10% to $16.99B, with diluted EPS of $2.03 vs $0.52 a year ago. The company announced a $10.9B acquisition of Apogee Therapeutics, expected to close in Q3 2026. R&D expenses increased, and the effective tax rate dropped to 15%.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-08-03Billionaire Ken Griffin Increased His Position in This Dividend King by 547%2026-08-19AbbVie Inc. Files 8-K Reporting Other Events2026-08-198-K2026-07-31 · 8-K10-Q2026-05-08 · 10-Q8-K2026-04-29 · 8-KFORM 8-K2026-02-26 · 8-K10-K2026-02-20 · 10-K